Drugs / trabodenoson
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02829996 | Aug 2016 → May 2017 | ocular hypertension, open-angle glaucoma | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01917383 | Aug 2013 → Aug 2014 | ocular hypertension, open-angle glaucoma | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02565173 | Sep 2015 → Nov 2016 | ocular hypertension, open-angle glaucoma | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2020-10-19 | Inotek Pharmaceuticals Corporation | Results Inotek Announces Study Results Demonstrating Neuroprotective Properties of Trabodenoson, its Lead Drug Candidate for Glaucoma inotekpharma.com ↗
Results of the study showed that trabodenoson provided 100% protection against the thinning of the ganglion cell layer (p<0.001 compared to vehicle-treated eyes). |
| 2020-10-19 | Inotek Pharmaceuticals Corporation | Results Inotek Canadian Pharmacy Presents Positive Phase 2 Data of Trabodenoson in Glaucoma inotekpharma.com ↗
Trabodenoson was found to reduce intraocular pressure (IOP) by approximately 7 mmHg at 28 days (p< 0.001) and was safe and well tolerated with very good ocular tolerability and less eye redness (hyperemia) than currently approved glaucoma treatments. |
| 2020-10-19 | Inotek Pharmaceuticals Corporation | Results Inotek Pharmaceuticals Presents Preclinical Data at ARVO Confirming that INO-8875 Lowers IOP by Increasing Outflow through the Trabecular Meshwork inotekpharma.com ↗
Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today presented results confirming the mechanism of action of the Company’s lead glaucoma candidate, INO-8875, as a trabecular meshwork outflow enhancer. |
| 2020-10-19 | Inotek Pharmaceuticals Corporation | Results Inotek Pharmaceuticals’ Novel Glaucoma Candidate, INO-8875, Significantly Reduces Intraocular Pressure in Phase 1/2 Study inotekpharma.com ↗
Inotek Pharmaceuticals today announced positive top-line results from a Phase 1/2 randomized, double-blind, placebo-controlled clinical trial of the Company’s lead candidate, INO-8875, in patients with glaucoma. |
| 2020-10-19 | Inotek Pharmaceuticals Corporation | Results Inotek Pharmaceuticals Presents Preclinical Data in Support of Novel Glaucoma Candidate, INO-8875 at ARVO inotekpharma.com ↗
Inotek Pharmaceuticals today presented positive preclinical results supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875. |
| 2008-11-13 | Inotek Pharmaceuticals Corporation | Regulatory Patents Issue for Inotek Pharmaceuticals’ Lead Clinical Candidates in Glaucoma and Contrast-Induced Nephropathy inotekpharma.com ↗
Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company’s two lead clinical compounds. |
All press releases naming this drug 9 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trabodenoson | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01917383 ↗ |
| Route | Other | “Ophthalmic eye drop” NCT01917383 ↗ |